XML 31 R16.htm IDEA: XBRL DOCUMENT

Intangible assets, net and Goodwill

12 Months Ended

Dec. 31, 2022

10. Intangible assets, net and Goodwill

The following table presents the Company’s acquired licenses and acquired IPR&D as of December 31:


	December 31,		December 31,
	2022		2021

	(in thousands)
Acquired licenses	$	2,346	$	4,755
Less accumulated amortization		(900)		(2,827)
Acquired licenses, net	$	1,446	$	1,928
Acquired IPR&D Intangible Asset		57,332		60,758
Intangibles, net	$	58,778	$	62,686

Acquired licenses

All acquired licenses are owned by uniQure biopharma B.V, a subsidiary of the Company. The remaining weighted average life is 11.5 years as of December 31, 2022. (December 31 , 2021 10.8 years.)

As of December 31, 2022, the estimated future amortization expense for each of the five succeeding years and the period thereafter is as follows:


Years	Amount
	(in thousands)
2023	$	126
2024		126
2025		126
2026		126
2027		126
Thereafter		816
Total	$	1,446

The amortization expense related to licenses for the year ended December 31, 2022 was $0.4 million (December 31, 2021: $1.2 million; December 31, 2020: $4.6 million). In 2020, the Company disposed of a number of licenses determined to have no alternative future use. The impairment expense related to licenses for the year ended December 31, 2022 was $0.0 million (December 31, 2021: $0.0 million; December 31, 2020 $0.3 million).

Acquired in-process research and development

As part of its acquisition of Corlieve as of July 30, 2021, the Company identified certain intangible assets related to an IPR&D Intangible Asset. Refer to Note 3 “Corlieve transaction”.

Goodwill

As part of its acquisition of Corlieve as of July 30, 2021, the Company recorded goodwill. Refer to Note 3 “Corlieve transaction”.